Endometrial ablation plus levonorgestrel releasing intrauterine system versus endometrial ablation alone in women with heavy menstrual bleeding: study protocol of a multicentre randomised controlled trial; MIRA2 trial.
Dysmenorrhoea
Endometrial ablation
Heavy menstrual bleeding
Hysterectomy
Levonorgestrel-releasing intrauterine system
Pelvic pain
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
27 06 2022
27 06 2022
Historique:
received:
27
04
2022
accepted:
17
06
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
30
6
2022
Statut:
epublish
Résumé
It is estimated that between 12 to 25% of women who undergo an endometrial ablation for heavy menstrual bleeding (HMB) are dissatisfied after two years because of recurrent menstrual bleeding and/or cyclical pelvic pain, with around 15% of these women ultimately having a hysterectomy. The insertion of a levonorgestrel-releasing intrauterine system (LNG-IUS) immediately after endometrial ablation may inactivate residual untreated endometrium and/or inhibit the regeneration of endometrial tissue. Furthermore, the LNG-IUS may prevent agglutination of the uterine walls preventing intrauterine adhesion formation associated with endometrial ablation. In these ways, insertion of an LNG-IUS immediately after endometrial ablation might prevent subsequent hysterectomies because of persisting uterine bleeding and cyclical pelvic pain or pain that arises de novo. Hence, we evaluate if the combination of endometrial ablation and an LNG-IUS is superior to endometrial ablation alone in terms of reducing subsequent rates of hysterectomy at two years following the initial ablative procedure. We perform a multicentre randomised controlled trial in 35 hospitals in the Netherlands. Women with heavy menstrual bleeding, who opt for treatment with endometrial ablation and without contraindication for an LNG-IUS are eligible. After informed consent, participants are randomly allocated to either endometrial ablation plus LNG-IUS or endometrial ablation alone. The primary outcome is the hysterectomy rate at 24 months following endometrial ablation. Secondary outcomes include women's satisfaction, reinterventions, complications, side effects, menstrual bleeding patterns, quality of life, societal costs. The results of this study will help clinicians inform women with HMB who opt for treatment with endometrial ablation about whether concomitant use of the LNG-IUS is beneficial for reducing the need for hysterectomy due to ongoing bleeding and/or pain symptoms. Trial registration Dutch Trial registration: NL7817. Registered 20 June 2019, https://www.trialregister.nl/trial/7817 .
Sections du résumé
BACKGROUND
It is estimated that between 12 to 25% of women who undergo an endometrial ablation for heavy menstrual bleeding (HMB) are dissatisfied after two years because of recurrent menstrual bleeding and/or cyclical pelvic pain, with around 15% of these women ultimately having a hysterectomy. The insertion of a levonorgestrel-releasing intrauterine system (LNG-IUS) immediately after endometrial ablation may inactivate residual untreated endometrium and/or inhibit the regeneration of endometrial tissue. Furthermore, the LNG-IUS may prevent agglutination of the uterine walls preventing intrauterine adhesion formation associated with endometrial ablation. In these ways, insertion of an LNG-IUS immediately after endometrial ablation might prevent subsequent hysterectomies because of persisting uterine bleeding and cyclical pelvic pain or pain that arises de novo. Hence, we evaluate if the combination of endometrial ablation and an LNG-IUS is superior to endometrial ablation alone in terms of reducing subsequent rates of hysterectomy at two years following the initial ablative procedure.
METHODS/DESIGN
We perform a multicentre randomised controlled trial in 35 hospitals in the Netherlands. Women with heavy menstrual bleeding, who opt for treatment with endometrial ablation and without contraindication for an LNG-IUS are eligible. After informed consent, participants are randomly allocated to either endometrial ablation plus LNG-IUS or endometrial ablation alone. The primary outcome is the hysterectomy rate at 24 months following endometrial ablation. Secondary outcomes include women's satisfaction, reinterventions, complications, side effects, menstrual bleeding patterns, quality of life, societal costs.
DISCUSSION
The results of this study will help clinicians inform women with HMB who opt for treatment with endometrial ablation about whether concomitant use of the LNG-IUS is beneficial for reducing the need for hysterectomy due to ongoing bleeding and/or pain symptoms. Trial registration Dutch Trial registration: NL7817. Registered 20 June 2019, https://www.trialregister.nl/trial/7817 .
Identifiants
pubmed: 35761328
doi: 10.1186/s12905-022-01843-6
pii: 10.1186/s12905-022-01843-6
pmc: PMC9235075
doi:
Substances chimiques
Contraceptive Agents, Female
0
Levonorgestrel
5W7SIA7YZW
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
257Informations de copyright
© 2022. The Author(s).
Références
Obstet Gynecol. 2002 Jun;99(6):1060-6
pubmed: 12052600
Cochrane Database Syst Rev. 2009 Oct 07;(4):CD001501
pubmed: 19821278
BJOG. 2005 Apr;112(4):470-5
pubmed: 15777447
J Minim Invasive Gynecol. 2020 Mar - Apr;27(3):774-780
pubmed: 31201942
J Minim Invasive Gynecol. 2015 Nov-Dec;22(7):1203-7
pubmed: 26122898
Clin Exp Obstet Gynecol. 2014;41(6):677-80
pubmed: 25566593
Obstet Gynecol. 2019 Dec;134(6):1269-1281
pubmed: 31764738
J Minim Invasive Gynecol. 2018 Nov - Dec;25(7):1255-1259
pubmed: 29550389
Health Econ. 2018 Jan;27(1):7-22
pubmed: 28833869
Acta Obstet Gynecol Scand. 2021 Oct;100(10):1779-1787
pubmed: 34165779
Fertil Steril. 1998 Jun;69(6):1063-6
pubmed: 9627293
BJOG. 2011 Nov;118(12):1528-31
pubmed: 21790952
Aust N Z J Obstet Gynaecol. 2007 Aug;47(4):335-40
pubmed: 17627692
Value Health. 2015 Sep;18(6):753-8
pubmed: 26409601
Am J Obstet Gynecol. 2002 Jun;186(6):1274-80; discussion 1280-3
pubmed: 12066109
BJOG. 2014 Mar;121(4):487-97
pubmed: 24245993
J Am Assoc Gynecol Laparosc. 2003 Nov;10(4):512-6
pubmed: 14738640
Stat Med. 1999 Mar 30;18(6):681-94
pubmed: 10204197
Pathol Res Pract. 2016 Sep;212(9):778-82
pubmed: 27461823
Cochrane Database Syst Rev. 2019 Jan 22;1:CD001501
pubmed: 30667064
Int J Womens Health. 2016 Jan 18;8:23-9
pubmed: 26848277
Gynecol Obstet Invest. 2010;70(3):145-8
pubmed: 20558986
Fertil Steril. 2004 Jul;82(1):160-6, quiz 265
pubmed: 15237006
Am J Obstet Gynecol. 2021 Feb;224(2):187.e1-187.e10
pubmed: 32795428
Acta Obstet Gynecol Scand. 2020 Nov;99(11):1554-1560
pubmed: 32609875
Value Health. 2016 Jun;19(4):343-52
pubmed: 27325326
Value Health. 2007 May-Jun;10(3):183-94
pubmed: 17532811
Fertil Steril. 2014 Feb;101(2):515-22
pubmed: 24331833